A rewarding quarter for Diamyd Medical

In her Message from the CEO, contained in the Year End Report published today, Elisabeth Lindner, President and CEO of Diamyd Medical, announced that the most recent quarter has been a successful and intensive one for the Company.

During the last quarter of the fiscal year, Diamyd Medical has made considerable progress with its successful start of the Phase III studies of the Diamyd® diabetes vaccine. The Company also gained a great deal of exposure through various conferences, publications and meetings. Above all the publication in the world’s most prestigious medical journal New England Journal of Medicine of the results from a previous Diamyd® study with children suffering from type 1 diabetes has proven to be an enormous success.

“In today’s turbulent financial climate, I am even more convinced that the business model used by Diamyd, a flexible virtual company with low fixed costs, is a determinative factor for stable growth and the achievement of our objective of becoming a pharmaceutical company in the area of diabetes”, comments Elisabeth Lindner, President and CEO of Diamyd.

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Subscribe

Documents & Links